Samsung Biologics (KRX:207940) subsidiary Samsung Bioepis and Israel's Teva Pharmaceutical entered into a licensing, development, and commercialization agreement for EPYSQLI, or eculizumab-aagh, biosimilar to Soliris in the US.
Samsung Bioepis will handle the development, regulatory registration, manufacturing, and supply, while Teva Pharmaceutical will manage the product's commercialization.
EPYSQLI is a complement inhibitor used to treat rare diseases such as paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome, Samsung Bioepis said Friday.
Financial details of the deal were undisclosed.
Shares of Samsung Biologics rose more than 1% in recent trade on Tuesday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。